Stereotactic Body Radiotherapy in Non-Small Cell Lung Cancer Patients: Assessment of Response and Toxicity at Single İnstitution

Küçük Resim Yok

Tarih

2022

Dergi Başlığı

Dergi ISSN

Cilt Başlığı

Yayıncı

Erişim Hakkı

info:eu-repo/semantics/openAccess

Özet

Objective: The aim of this study is to assess the efficacy and acute toxicity of stereo tactic body radiotherapy (SBRT) for either primary or metastatic masses of lung tumors. Material and Methods: Analysis was performed on 110 lung tumor masses (primarily non-small cell origin, a small proportion was metastatic) patients treated by CyberKnife® in our clinic between February 2010 and July 2015. Doses had been delivered ranged 20–60 Gy, in one to seven once-daily fractions, depending on tumor size and location. Results: The median follow-up duration after SBRT was 29 months (range 14, 75–40 months). The median overall survival (OS) was 31.62 months (95% CI, 24.06–37.93 months). 3-year survival was 42% and 5-year survival was 22%. Conclusion: Lung tumors (primary or metastatic) treated by SBRT had better treat ment response and less toxicity compared with conventional radiotherapy schedules. If available-depending on size and location of the tumor(s) - SBRT is the most afford able; preferable option.

Açıklama

Anahtar Kelimeler

Kaynak

İzmir Göğüs Hastanesi Dergisi

WoS Q Değeri

Scopus Q Değeri

Cilt

36

Sayı

2

Künye